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INTRODUCTION
Brain endothelial cells (BEC), highly specialized 
endothelial cells, are the main constituents of the 
blood-brain barrier (BBB). Structural specializa-
tions of BEC include highly organized tight junc-
tions, the absence of expression of MHC II mol-
ecules, and highly developed transport systems (Prat 
et al., 1999). Due to these characteristics, BEC have 
a decisive role in the selection of substances and 
cells transported in or out of the CNS. In connec-
tion with migration of cells to the CNS, BEC display 
various adhesive molecules on their surface, such as 
VCAM-1, ICAM-1, PECAM-1, ICAM-2, CCL19, 
and E and P selectin in physiological and patho-
logical conditions (Engelhardt and Ransohoff, 2005; 
Ranshoff et al., 2003, Gavins et al., 2007), which 
allow them to communicate directly with leukocytes 
involved in normal immune surveillance or with 
activated cells infiltrating the CNS. Activated T cells 
can cross the compact BBB, and if they recognize 
target structure(s) in the CNS, as a consequence 
various soluble factors are released that cause BEC 
to become less restrictive, leading to increased 
lymphocyte trafficking across the BBB as an early 
event in inflammatory CNS diseases (Archambault 
et al., 2005; Becher et al., 2006). Besides controlling 
transport of leukocytes across the BBB, BEC are 
also able to influence immune functions of CNS 
resident cells and blood-borne cells through secre-
tion of different substances, including nitric oxide 
(NO), prostaglandins, and cytokines such as IL-6, 
IL-8, MCP, RANTES, TNF-α, IL-1, GM-CSF, IL-10, 
and endothelin-1 (Zhao et al., 2006; Konsman et al., 
2007; Matsumura and Kobayashi, 2004; Reyes et al., 
1999).
The pro-inflammatory T cell cytokines IFN-γ 
and IL-17 are considered to be among major cul-
prits in the CNS inflammatory disease multiple 
sclerosis (MS) and its animal model, experimental 
autoimmune encephalomyelitis (EAE) (Segal, 2005; 
Wheeler and Owens, 2005). A pivotal Th1 cytokine, 
IFN-γ  activates macrophages and up-regulates pro-
duction of a variety of pro-inflammatory mediators 
such as IL-12, IL-15, TNF-α, interferon-inducible 
protein-10, and inducible NO synthase (iNOS) in 
different cell types. It is known that IFN-γ–secreting 
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Th1 cells are present in the CNS before the onset of 
clinical symptoms and disappear during the remis-
sion phase of EAE (juedes et al., 2000; Renno et al., 
1995). They are also present in MS lesions (Traugott 
et al., 1983). Treatment with IFN-γ exacerbates 
MS (Panitch et al., 1987), and mice deficient in T-
bet – master regulator of Th1 differentiation – are 
resistant to EAE (Nath et al., 2006). Moreover, it 
has recently been shown that IFN-γ largely con-
tributes to myelin destruction in a mouse model 
of demyelination (Mana et al., 2006). Recent data 
indicate that the newly discovered Th17 population 
is the pathogenic population in EAE pathogenesis 
(Aggarwal et al., 2003; Langrish et al., 2005). It has 
been demonstrated that Th17 cells are characterized 
by the production of a distinct profile of effector 
cytokines, including IL-17 (IL-17A), IL-17F, TNF-α, 
and IL-6 (Langrish et al., 2005; Betteli et al., 2008). 
Moreover, IL-17 is important in the induction and 
maintenance of inflammation, as it can induce the 
production of other cytokines and chemokines from 
a variety of cell types and coordinate the recruitment 
of neutrophils and monocytes to the site of inflam-
mation (Kolls and Linden, 2004). It was shown 
that in MS patients, IL-17 mRNA and protein were 
increased in both brain lesions and mononuclear 
cells isolated from blood and cerebrospinal fluids 
(Lock et al., 2002; Matusevicius et al., 1999). Further, 
induction of  EAE is blocked in mice deficient in 
IL-23, which promotes the differentiation of IL-17–
producing cells (Cua et al., 2003); adoptive transfer 
of autoantigen specific Th17 cells induced EAE 
(Langrish et al., 2005); and finally, the development 
of EAE was significantly suppressed in IL-17 knock-
out mice or mice treated with anti–IL-17 vaccine 
(Komiyama et al., 2006; Wraith, 2006).
In light of the intimate relationship between 
BEC and peripherally activated T lymphocytes and 
the importance of IFN-γ and IL-17 for the patho-
genesis of MS and EAE, our aim was to investigate 
if BEC can influence production of these cytokines 
in T lymphocytes. We report here that BEC potently 
modulate IFN-γ (but not IL-17) gene expression 
and secretion. This influence could be of potential 
importance for regulation of the auto-aggressive T 
cell response.
MATERIALS AND METHODS
Murine brain endothelial cell line bEnd.3 was 
obtained from the American Type Culture Collection 
(ATTC, MD, USA). The cells were grown in HEPES-
buffered RPMI-1640 medium (Sigma, Germany) 
containing 10% heat-inactivated fetal bovine serum 
(PAA Chemicals, Austria), antibiotic/antimycotic, 
and 2 mM glutamine. Cells from 22 to 25 passages 
were used for all experiments. Cervical lymph nodes 
(LN) were isolated from BALB/c mice and mashed 
through steel net into the medium. The resulting cell 
suspension (LNC) was centrifuged and resuspended 
for final counting and use in experiments. Adequate 
measures were taken to minimize pain or discom-
fort of the animals. For the experiments with co-
cultivation, bEnd.3 cells (2x105/well) were seeded 
in 24-well plates (Sarsted, Germany) and incubated 
overnight. Subsequently, LNC (4x106/well) were 
added to cultures, either directly onto bEnd.3 or 
into tissue culture inserts (0.2 µM Anapore mem-
brane, Nunc, Denmark) that prevented contact 
between these two cell populations. The cells were 
cultivated for 6 or 24 h under standard condi-
tions (5% CO2, 37oC) in the presence or absence 
of 2.5 µg/ml of concanavalin A (ConA, Pharmacia, 
Sweden). Afterwards, cell culture supernatants were 
collected and frozen until used in ELISA (mouse 
IL-17, IFN-γ, and IL-12 ELISA DuoSets, R&D 
Systems, MN, USA), and the pelleted cells were used 
for total RNA isolation and subsequent real time 
(RT)-PCR. Ribonucleic acid was reverse transcribed 
using  random hexamer primers and MMLV reverse 
transcriptase (Fermentas, Lithuania). The RT-PCR 
procedure was performed in the ABI PRISM 7500 
Sequence Detection System (Applied Biosystems, 
CA, USA) using the TaqMan Universal PCR Master 
Mix (Applied Biosystems). Thermocycler condi-
tions comprised the initial step (50oC for 2 min and 
subsequent heating to 95oC for 10 min). This was 
followed by a two-step PCR program at 95oC for 
15 sec and 60oC for 60 sec for 40 cycles. The PCR 
primers and probes used were as follows: IFN-γ 
forward primer 5'-TGG CAT AGA TGT GGA AGA 
AAA GAG -3'; IFN-γ - reverse primer 5'-TGC AGG 
ATT TTC ATG TCA CCA T-3'; IFN-γ  probe FAM 
5’-TTT TGC CAG TTC CTC CAG ATA TCC AAG 
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AAG A-3’ TAMRA; IL-17 forward primer 5’-ATC 
AGG ACG CGC AAA CAT G-3’; IL-17 reverse 
primer 5’-TGA TCG CTG CTG CCT TCA C -3’; IL-
17 probe FAM 5’-CTT CAT CTG TGT CTC TGA 
TGC TGT TGC TGC-3’ TAMRA; β-actin forward 
primer 5’-GCT TCT TTG CAG CTC CTT CGT-3’; 
β-actin reverse primer 5'-CCA GCG CAG CGA 
TAT CG-3'; and β-actin probe VIC 5'-CAC CCG 
CCA CCA GTT CGC CAT-3' TAMRA. Expression 
of IL-17 and that of IFN-γ were determined relative 
to expression of β-actin. Relative gene expression 
in cultures grown in a medium without additional 
treatment was adopted as the value of an arbitrary 
unit. The results are presented as means ± SD of 
values obtained in repeated experiments. Student’s 
t test was performed for statistical analysis of the 
differences observed. A p value less than 0.05 was 
considered significant.
Abbreviations: CNS – central nervous system; ConA 
– concanavalin A; EAE – experimental autoimmune 
encephalomyelitis; IFN – interferon; IL – interleu-
kin; LNC – lymph node cells; MHC – major histo-
compatibility complex; MS – multiple sclerosis; Th 
– helper T cells.
RESULTS
Inasmuch as interaction of BEC and T cells migrat-
ing to the CNS parenchyma is important for the 
initiation of inflammation in the CNS, we exam-
ined the influence of bEnd.3 cells on IFN-γ and 
IL-17 generation in T cells. Production of IFN-γ 
in LNC was markedly inhibited in the presence of 
bEnd.3 cells after 6 or 24 h of cultivation (Fig. 1). A 
stronger effect was observed if the contact between 
cells was inhibited by a tissue culture insert. On the 
other hand, IL-17 release from LNC was just weakly 
modified in the presence of bEnd.3 (Fig. 1). The 
observed effect on cytokine production was not a 
consequence of decline in the number of LNC in co-
cultivation, as was deduced from cell viability and 
cell number determination by MTT assay and try-
pan blue staining, respectively (data not shown). In 
order to explore if the observed influence of bEnd.3 
on cytokine secretion by LNC was realized through 
gene expression modulation, LNC from co-cultiva-
tions in the presence of tissue culture inserts were 
centrifuged, RNA from pelleted cells was isolated, 
and RT-PCR analysis was performed. To judge from 
cytokine secretion, mRNA expression of IFN-γ (but 
not IL-17) was markedly down-regulated in the 
presence of bEnd.3 cells after 6 or 24 h of cultivation 
(Fig. 2). Thus, the influence of b.End3 cells on pro-
duction of IFN-γ was most likely mediated through 
inhibition of its gene expression. Importantly, there 
was a marked difference in the influence of bEnd.3 
on IFN-γ and IL-17, as these cells strongly inhibited 
the former but had only a minor (if any) effect on 
the latter.
Having in mind that IL-12 is a well-known 
promoter of IFN-γ synthesis, we explored the influ-
ence of bEnd.3 cells on IL-12 production in order to 
find out if the observed inhibitory effect of bEnd.3 
cells on IFN-γ production and gene expression was 
achieved through inhibition of IL-12 production. 
Significant inhibition of IL-12 production in co-cul-
tivations was observed when the cells were separated 
with a tissue culture insert (Fig. 3). Interestingly, in 
the presence of direct cell-cell contact between these 
cells, there was no inhibition of IL-12 secretion. At 
the same time, bEnd.3 cells did not produce detect-
able amounts of IL-12 in our experiments. Almost 
the exact same results were obtained in co-cultures 
lasting for 6 and 24 h, thus clearly suggesting that 
there was a correlation between IFN-γ and IL-12 
secretion in the absence (but not in the presence) of 
direct contact between bEnd.3 cells and LNC.
DISCUSSION
This study attempted to clarify if BEC can affect pro-
duction of marker Th1 and Th17 cytokines, IFN-γ 
and IL-17, respectively. The bEnd.3 cells used in the 
investigation strongly reduced IFN-γ (but not IL-17) 
production in vitro, thus implying a cytokine-specif-
ic effect of brain endothelial cells on lymphocytes.
Although there are numerous data describing 
the influence of T cells and their cytokines on brain 
endothelium, and the function of BBB in particular 
(Engelhardt and Ransohoff, 2005), investigations of 
the opposite process are not so abundant. Regarding 
IFN-γ, there is a paper that seems to contradict our 
work, as it reports that human BEC do not influ-
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Fig. 1. Influence of bEnd.3 cells on IFN-γ and IL-17 production 
in ConA-stimulated LNC. Lymph node cells were cultivated 
alone or co-cultivated with bEnd.3 cells for 6 h (A) or 24 h (B) 
in the absence (medium) or presence of ConA (2.5 µg/ml) with 
(insert) or without (contact) a tissue culture insert. Cell-free 
culture supernatants were subsequently collected and analyzed 
for the concentration of IL-17 and IFN-γ by ELISA. Data ob-
tained from 3-7 experiments are presented as means ± SD of 
values obtained in individual experiments. *p<0.05 represents 
statistical significance of the difference in relation to cultures of 
LNC cultivated alone and stimulated with ConA.
Fig. 2. Influence of bEnd.3 cells on IFN-γ and IL-17 gene ex-
pression in ConA-stimulated LNC. Lymph node cells (2x105/
well) were cultivated with or without ConA (2.5 µg/ml) in the 
absence or presence of bEND.3. In co-cultivations, bEND and 
LNC were separated by tissue-culture inserts. After 6 h (A, B) 
and 24 h (C, D) of cultivation, RNA was isolated, and reverse 
transcription followed by RT- PCR analysis for IFN-γ (A, C) 
and IL-17 (B, D) was performed. Data obtained from two ex-
periments are presented as means ± SD of values obtained in 
individual experiments. *p<0.05 represents statistical signifi-
cance of the difference in relation to cultures of LNC cultivated 
alone and stimulated with ConA.
Fig. 3. Influence of bEnd.3 cells on IL-12 production in ConA-stimulated LNC. Lymph node cells were culti-
vated alone or co-cultivated with bEnd.3 cells for 6 h (A) or 24 h (B) in the absence (medium) or presence of 
ConA (2.5 µg/ml) with (insert) or without (contact) a tissue culture insert. Cell-free culture supernatants were 
subsequently collected and analyzed for the concentration of IL-12. Data obtained from 3-5 experiments are 
presented as means ± SD of values obtained in individual experiments. *p<0.05 represents statistical significance 
of the difference in relation to cultures of LNC cultivated alone and stimulated with ConA.
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ence IFN-γ production in Th1 cells (Biernacki et al., 
2001). However, differences in the species, purity of 
lymphocytes used, and stimulation employed in the 
two studies could easily account for the discrepancy 
in data. In their study, Biernacki et al. (2001) puri-
fied Th1 cells from peripheral blood of healthy sub-
jects and stimulated them with myelin basic protein 
(MBP). The obvious advantages of their system are 
purity of the used populations and antigen specific-
ity of the T cell response. On the other hand, using 
a mixed population isolated from lymph nodes and 
stimulation with a polyclonal T cell activator (ConA) 
more clearly elucidates the composition of cells 
infiltrating CNS and the inflammatory milieu in 
later phases of the autoimmune process in the CNS. 
Whatever the case, here we record a pronounced 
effect of BEC on IFN-γ production. Interestingly, 
the reduction in IFN-γ correlated with reduction of 
IL-12 only in the event that bEnd.3 cells and LNC 
were separated by tissue culture inserts. It is pos-
sible that regulation of IL-12 production is exerted 
both by cell-cell contact and by soluble products, 
the former being largely positive and capable of 
attenuating the inhibitory effects of soluble factors. 
In the absence of these stimulatory cellular interac-
tions, IL-12–producing cells remain exposed only to 
soluble factors and the net effect is inhibition of IL-
12 production. It therefore seems that down-regula-
tion of IL-12 production in co-cultivations could 
be responsible for the effect on IFN-γ, but only if 
bEnd.3 and LNC are not in direct cell-cell contact. 
In direct contact with LNC, bEnd.3 do not inhibit 
IL-12 production and have a weaker effect on IFN-γ 
generation. There are many other cytokines that are 
important for IFN-γ regulation, and bEnd.3 could 
affect their production as well. Inasmuch as IL-12 
can be just one of the essential factors for IFN-γ 
synthesis, if IL-12 is inhibited there is inhibition of 
IFN-γ as well, but if IL-12 is not inhibited there is 
still room for IL-12–independent regulation of IFN-
γ production to take place. This difference in the 
effect regarding contact between bEnd.3 and LNC 
could be of importance for understanding data indi-
cating that Th1 cells (as major producers of IFN-γ) 
have the ability to migrate across the BBB (Biernacki 
et al., 2001; Prat et al., 2002), but that their encepha-
litogenic potential is weak in comparison to Th17 
cells. Since transmigration is a complex process 
involving at least two crucial steps: 1. entrance into 
perivascular spaces, and 2. passage to CNS paren-
chyma (Bechmann et al., 2007), it could be that 
BEC in direct contact during the first step weakly 
influence IFN-γ production of transmigrating Th1 
cells and allow their entrance into perivascular 
spaces, although already reducing their functional-
ity. In the second step, BEC acting through soluble 
factors might reduce IFN-γ production and Th1 
functionality (including encephalitogenicity) more 
aggressively. If we suppose that production of IFN-γ 
is a clear marker of Th1 functionality, the suggested 
speculation is even more attractive.
On the other hand, bEnd.3 had a limited (if 
any) effect on IL-17 generation in LNC. It therefore 
seems reasonable to assume that Th17 cells pass 
the BBB with no major effect on their functionality. 
Thus, this result is in accordance with the presumed 
importance of Th17 cells for CNS autoimmunity. 
There are plentiful data indicating a high encepha-
litogenic potential of Th17. A pivotal pathogenic 
role for IL-17 in the CNS autoimmune response 
is substantiated by attenuation of EAE with IL-17 
neutralization by anti–IL-17 antibodies or in mice 
genetically deficient in IL-17 or the IL-17 receptor 
(IL-17R) (Weaver et al., 2007; Betteli et al., 2008; 
Kramer and Gafen, 2007). First indications about 
the importance of Th17 cells for the pathogenesis of 
MS were significant increase in IL-17 gene expres-
sion and elevation in the number of IL-17–pro-
ducing CD4+ and CD8+ T cells in active lesions 
in comparison with silent lesions or normal tissue 
(Lock et al., 2002; Tzartzos et al., 2008). Importantly, 
it has recently been reported that human blood-
brain barrier (BBB) endothelial cells in MS lesions 
express receptors for IL-17, and that IL-17 disrupts 
BBB tight junctions both in vitro and in vivo (Kebir 
et al., 2007). It has also been shown that Th17 lym-
phocytes transmigrate efficiently across BBB endo-
thelial cells, highly express granzyme B, kill human 
neurons, and promote CNS inflammation through 
CD4+ lymphocyte recruitment (Kebir et al., 2007). 
Taken together, these recent data clearly suggest 
the importance of Th17 for the pathogenesis of MS. 
Significantly, there is a recent finding that functional 
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perivascular myeloid CNS dendritic cells arise as 
a consequence of migration of monocytes across 
the human BBB through the concerted actions of 
BBB-secreted transforming growth factor-beta and 
granulocyte-macrophage colony-stimulating factor 
(Ifergan et al., 2008). Thus, there is the possibility 
that BEC even promote Th17 propagation within 
the CNS.
Our results clearly suggest the ability of BEC to 
inhibit IFN-γ and inability to interfere efficiently 
with IL-17 production in activated T cells in vitro. 
Such a finding is important for understanding the 
different encephalitogen potentials of Th1 and Th17 
cells. Furthermore, it contributes to the growing 
body of data that should allow for the creation of 
more efficient therapy of neuro-inflammatory dis-
orders.
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ЋЕЛИЈЕ МИШЈЕГ МОЖДАНОГ ЕНДОТЕЛА ОСТВАРУЈУ РАЗЛИЧИТ УТИЦАЈ НА 
ПРОДУКЦИЈУ ИНТЕРФЕРОНА-γ И ИНТЕРЛЕУКИНА-17 IN VITRO
Миљана МоМчиловић1, Ђ. Миљковић1 и Марија Мостарица стојковић2
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Ће­ли­је­ мо­жда­но­г е­ндо­те­ла­ су о­сно­в­ни­ е­ле­ме­н­
ти­ гра­ђе­ крв­но­­мо­жда­не­ ба­ри­је­ре­, структуре­ ко­ја­ 
ко­нтро­ли­ше­ ула­за­к ће­ли­ја­ и­мунско­г си­сте­ма­ у па­ре­н­
хи­м CNS. На­ш ци­љ је­ би­о­ да­ се­ и­спи­та­ ути­ца­ј о­в­и­х 
ће­ли­ја­ на­ про­дукци­ју и­нте­рфе­ро­на­­га­ма­ и­ и­нте­рле­у­
ки­на­­17, ка­о­ кључ­ни­х про­и­нфла­ма­то­рни­х ци­то­ки­на­ 
у не­уро­и­нфла­ма­ци­ји­. Збо­г то­га­ смо­ в­рши­ли­ ко­­кул­
ти­в­а­ци­ју bEnd.3 ли­ни­је­ мо­жда­но­г е­ндо­те­ла­ и­ ће­ли­­
ја­ ли­мфно­г ч­в­о­ра­, и­ то­ у при­суств­у и­ли­ о­дсуств­у 
ди­ре­ктно­г ко­нта­кта­ ме­ћу на­в­е­де­ни­м по­пула­ци­ја­ма­, 
и­ о­дре­ђи­в­а­ли­ е­кспре­си­ју ге­на­ и­ про­дукци­ју на­в­е­де­­
ни­х ци­то­ки­на­. По­ка­за­ло­ се­ да­ bEnd.3 ће­ли­је­ по­те­нт­
но­ и­нхи­би­ра­ју про­дукци­ју и­нтeрфе­ро­на­­га­ма­, а­ли­ 
не­ и­ и­нте­рле­уки­на­­17. Та­ко­ђе­, ме­ри­ли­ смо­ и­ про­дук­
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ци­ју и­нте­рле­уки­на­­12, гла­в­но­г сти­мула­то­рно­г ци­то­­
ки­на­ за­ про­дукци­ју и­нте­рфе­ро­на­­га­ма­, и­ по­ка­за­ли­ 
да­ је­ и­ ње­го­в­а­ про­дукци­ја­ сма­ње­на­ у ко­­култи­в­а­ци­ји­ 
bEnd.3 ће­ли­ја­ и­ ће­ли­ја­ ли­мфно­г ч­в­о­ра­. За­па­же­на­ 
ра­зли­ч­и­то­ст у де­ло­в­а­њу ће­ли­ја­ мо­жда­но­г е­ндо­те­ла­ 
на­ дв­а­ о­сно­в­на­ про­и­нфла­ма­то­рна­ ци­то­ки­на­ је­ о­д зна­­
ч­а­ја­ за­ ра­зуме­в­а­ње­ ко­мпле­ксно­г про­це­са­ ре­гула­ци­је­ 
и­нфла­ма­ци­је­ у CNS.
